Multivariate Cox regression analysis model
Variable . | n . | Hazard ratio . | CI, 95% . | P . |
|---|---|---|---|---|
| Age | 47 | 1.02 | 0.97-1.06 | .50 |
| Disease stage at diagnosis | 47 | 8.66 | 3.0-25.1 | .0001 |
| β2-microglobulin | 45 | 3.08 | 1.06-8.95 | .039 |
| ZAP-70 status | 42 | 3.58 | 1.14-11.27 | .029 |
| CD38 status | 47 | 1.83 | 0.48-6.94 | .37 |
| HLA-G status | 47 | 4.81 | 1.74-13.29 | .002 |
Variable . | n . | Hazard ratio . | CI, 95% . | P . |
|---|---|---|---|---|
| Age | 47 | 1.02 | 0.97-1.06 | .50 |
| Disease stage at diagnosis | 47 | 8.66 | 3.0-25.1 | .0001 |
| β2-microglobulin | 45 | 3.08 | 1.06-8.95 | .039 |
| ZAP-70 status | 42 | 3.58 | 1.14-11.27 | .029 |
| CD38 status | 47 | 1.83 | 0.48-6.94 | .37 |
| HLA-G status | 47 | 4.81 | 1.74-13.29 | .002 |
CI indicates confidence interval.
The cut-off levels used in the analysis were as follows: age, 60 years; disease stage at diagnosis, Binet stage A versus B versus C; β2-microglobulin, 3.5 mg/L; ZAP-70 or CD38 status, 20% positive cells; and HLA-G status, 23% positive cells. Because of missing data in a substantial proportion of patients, the prognostic marker thymidine kinase (cf Table 1) was not included in the analysis.